P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

MLA

Bo Lu, et al. “P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC.” Journal of Thoracic Oncology, vol. 13, Oct. 2018, pp. S1028–29. EBSCOhost, https://doi.org/10.1016/j.jtho.2018.08.1978.

APA

Bo Lu, Grace L. Lu-Yao, R. Axelrod, Dawn Poller, Maria Werner-Wasik, Ralph Zinner, D.C. Hooper, Scott W. Cowan, B. Leiby, C. Solomides, Hushan Yang, Jennifer Johnson, L. Harshyne, Athanassios Argiris, Nathaniel R. Evans, & L. Phan. (2018). P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC. Journal of Thoracic Oncology, 13, S1028–S1029. https://doi.org/10.1016/j.jtho.2018.08.1978

Chicago

Bo Lu, Grace L. Lu-Yao, R. Axelrod, Dawn Poller, Maria Werner-Wasik, Ralph Zinner, D.C. Hooper, et al. 2018. “P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC.” Journal of Thoracic Oncology 13 (October): S1028–29. doi:10.1016/j.jtho.2018.08.1978.